Product Pathways - Growth Factors/Cytokines
Human Interleukin-28B (hIL-28B/IFN-λ3) #8796
|8796LF||50 µg (Carrier Free)||---||In Stock||---|
|8796LC||50 µg (With Carrier)||---||In Stock||---|
|8796SC||10 µg (With Carrier)||---||In Stock||---|
|8796SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-28B (hIL-28B) Arg26-Val196 (Accession #NP_742151) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hIL-28B contains no "tags" and the nonglycosylated protein has a calculated MW of 19,264. DTT-reduced and non-reduced protein migrate as 21 kDa polypeptides with non-reduced protein having slightly greater mobility due to intramolecular cystines. The expected amino-terminal RLRGA of recombinant hIL-28B was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-28B. All lots are greater than 98% pure.
The bioactivity of recombinant hIL-28B was determined in a virus protection assay. The ED50 of each lot is between 0.4-9 ng/ml.
The purity of recombinant hIL-28B was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-28B and staining overnight with Coomassie Blue.
The bioactivity of hIL-28B was determined in a virus protection assay. Hep G2 cells were pre-treated with increasing concentrations of hIL-28B for 24 hours and then inoculated with encephalomyocarditis virus (EMCV) and incubated for an additional 48 hours. Cells were then incubated with a tetrazolium salt and the OD450-OD650 was determined.
Less than 0.01 ng endotoxin/1 μg hIL-28B.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-28B. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-28B is a member of the Interferon λ family of cytokines, which includes IL-29 and IL-28A (1). IL-28B is produced by a number of cell types and shares many functions with Type I Interferons (1-3). IL-28B exhibits anti-viral activities in vitro and in vivo (1,2). Investigators have found that IL-28B directly inhibits tumor cell proliferation and promotes anti-tumor immune responses in vivo (1,3). The IL-28 receptor is a heterodimer of the IL-28Rα and IL-10RI (1). IL-28A activates Stat1, Stat3, and Stat5 (1). IL-28Rα expression is limited to a few cell types, including plasmacytoid DC and epithelial cells (1).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.